Evaluation of this combination was prompted by pre-clinical studies demonstrating that anti-VEGF therapies reduce VEGF associated immune suppression in the tumor microenvironment and promote the increase of tumor infiltrating lymphocytes, thereby enhancing anti-PD-1 or PD-L1 efficacy [32,33,34,35,36]. The gene discussed is CD274; the disease is neoplasm.